Our Technology

At Geneseeq, we constantly strive to advance our scientific research because we know that hard work translates to cutting-edge technologies for patients. Our extensive collaborations are formed on the basis of shared values and the common goal of improving patient care.

We are continuously evolving our sequencing technology as we gain new knowledge. This ensures an optimized workflow – from sample preparation and machine-learning to exclusive genomic databases – and a very high sequencing capacity. To date, we have sequenced 900,000+ clinical samples, with high sensitivity and specificity and a turnaround time of just 5 business days*.

See What We Can Do

* Typical turnaround time for clinical testing from receipt of specimen in our central laboratory is 5 business days.

Accurate and rapid results to help reduce time to treatment

Technology ATG-Seq


Automated Triple Groom Sequencing

Cell-free DNA (cfDNA) are DNA fragments released into blood plasma by dead cells, among which is circulating tumor DNA (ctDNA) derived from cancer cells. ctDNA is a promising, non-invasive biomarker for cancer detection and molecular diagnosis. However, due to its low proportion to total cfDNA, and variability in different cancer types and stages of disease, current genetic testing methods offer insufficient detection sensitivity and specificity. Multiple technical barriers such as high background noise from PCR, target enrichment processes and sequencing errors are also prevalent. Our ATG-Seq™ technology utilizes ultra-deep sequencing with three levels of error correction to take ctDNA detection sensitivity and specificity to a new level.

ATG-Seq™ Technology

Ultra-deep sequencing with three levels of error correction

Icon Item 1

BBAM (Bi-Barcoded Articulation of Mutation) effectively eliminates errors at DNA double-strand level through unique sequencing library preparations and bioinformatic analysis pipelines

Icon Item 2

DDAM (DNA Duplex Assisted Mutation-Decoder) effectively eliminates errors at DNA single-strand level through unique sequencing library preparations and bioinformatic analysis pipelines

Icon Item 3

BISC (Background In Silico Correction) leverages our large healthy individual baseline database and machine learning algorithms to further reduce background noise and ensure high specificity and precision

See our products with ATG-Seq™ technology



Free NGS-based CNV analysis from disturbance

Next-generation sequencing (NGS) involves multiple steps of polymerase chain reaction (PCR) amplification and target enrichment. Each of these steps introduces inevitable bias. Consequently, the amounts of sequencing reads mapped to target genes rarely show a linear relationship proportional to the copy number of the genes, rendering it extremely difficult for copy number variation (CNV) analysis. To circumvent this technical limitation, we developed a revolutionary TRANQUIL™ algorithm to boost the signal-to-noise ratio and performed a comprehensive validation to characterize the pipeline performance. TRANQUIL™ proves to be highly proficient at accurately detecting both gene-level and exon-level CNV events.

Technology Mercury


Early Cancer Detection Using Multi-omics Biomarkers

Early detection, diagnosis and treatment of cancer can significantly improve patients’ survival and quality of life. Tumors are constantly releasing fragmented genomic DNA into the bloodstream, but the signal can be too weak to be picked up at early stages by existing testing methods. Leveraging our large liquid biopsy multi-omics database of early stage cancer patients and healthy individuals, we identified genetic and epigenetic biomarkers of circulating tumor DNA in different cancer types. Mercury™ employs highly sensitive and high-throughput technology to target these biomarkers to detect cancer as early as possible using liquid biopsies.

Logo Mercury
Learn More About Our Progress


Longitudinal Post-operative Surveillancefor Early Detection of Cancer Relapse

Early stage cancer patients can attain durable disease-free survival after curative surgery. However, there are still a substantial number of patients suffering from local recurrence or distant metastasis. Calibrate™ is a highly sensitive non-invasive technology that dynamically monitors circulating tumor DNA in the bloodstream using ATG-Seq™ technology. It incorporates machine learning and mathematic models generated from our exclusive database to predict the probability of disease relapse. Calibrate™ aims to detect cancer recurrence earlier than clinical imaging such as CT scans. In patients who are on post-operative drug treatments, it also reveals resistance mechanisms and prompts adjustment of treatment strategies.

Logo Calibrate
Learn More About Our Progress
Technology Calibrate


Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us